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Abstract 26 
Familial Adenomatous Polyposis (FAP) is characterised by the development of 27 
hundreds to thousands of colorectal adenomas and results from inherited or somatic 28 
mosaic variants in the APC gene.  Index patients with suspected FAP are usually 29 
investigated by APC coding region sequence and dosage analysis in a clinical diagnostic 30 
setting.  The identification of an APC variant which affects protein function enables 31 
predictive genetic testing to guide the management of family members. This report 32 
describes a 4-generation family with a phenotype consistent with FAP, but in which an 33 
APC variant had not been identified, despite testing. To explore this further, 34 
quantitative PCR (qPCR) was employed to assess APC transcription, demonstrating 35 
reduced levels of APC RNA.  Next generation sequencing (NGS) identified the APC 36 
5 UT‘/ E o   aria t, c.-190 G>A, that had been reported previously in another FAP 37 
family with APC allelic imbalance.  Quantitative RNA studies and DNA sequencing of 38 
the APC promoters/ Exon 1 may be useful diagnostically for patients with suspected 39 
FAP when coding region variants cannot be identified. 40 
 41 
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Introduction 49 
Familial Adenomatous Polyposis (FAP), due to germline or somatic mosaic variants 50 
affecting APC, is the second most common cause of inherited colorectal cancer (CRC) 51 
after Lynch Syndrome.  FAP affects approximately 1 in 8000 individuals (reviewed in ref 52 
1; reviewed in ref 2; reviewed in ref 3).  It is characterised by the development of 53 
hundreds to thousands of colorectal adenomas and, if untreated, will progress to CRC.  54 
In addition to FAP, there are several other, rarer syndromes which are characterised by 55 
multiple, though usually fewer, colorectal adenomas and an increased risk of CRC.  56 
These include MUTYH-Associated Polyposis (MAP) (ref 4), Polymerase-Proofreading 57 
Associated Polyposis (PPAP) (ref 5), NTHL1-Associated Polyposis (NAP) (ref 6) and 58 
MSH3-Associated Polyposis (ref 7).   59 
 60 
The identification of causative variants in families with inherited polyposis syndromes 61 
is important for the prevention of CRC. Good clinical practice includes referral of 62 
patients with multiple colorectal adenomas for genetic counselling and consideration 63 
of diagnostic testing of APC and other polyposis genes.  Well over 90% of patients with 64 
a phenotype of classical FAP have a germline APC variant affecting protein function 65 
identified through sequencing of coding exons and deletion/duplication analysis via 66 
multiplex ligation-dependent probe analysis (MLPA) (ref 8). Of those patients with an 67 
attenuated phenotype, with <100 adenomas, APC, MUTYH or other causative germline 68 
variants are detected in only 20-50% of cases (ref 8).  The monogenic mechanisms 69 
potentially operating in the group who have no APC variant identified (NVI) include 70 
 
promoter and other non-coding variants, somatic mosaicism, the involvement of other 71 
genes and epigenetic effects. 72 
 73 
This paper describes a 4-generation family with a clinical diagnosis of FAP. Despite 74 
genetic diagnostic testing performed in several expert centres, the genetic basis for 75 
the disease had not been determined.  76 
 77 
Methods 78 
Subjects 79 
A study at Cardiff U i ersit , Ge eti  Me ha is s i  Colore tal Pol posis  (appro ed 80 
by the NHS Research Ethics Committee for Wales: REC 3, study 12/WA/0071) is 81 
currently investigating patients with at least 10 colorectal polyps who have no 82 
pathogenic APC variant identified (NVI) on genetic testing in a clinical diagnostic 83 
setting.  All patients recruited to the study give written, informed consent.   84 
One of the probands (Individual 2.1, Figure 1) participating in the study was a 44-year 85 
old female who had undergone a colectomy and proctectomy for clinical FAP.  At least 86 
11 other family members were also affected (Figure 1).  The family history was 87 
provided by recruited family members but detailed clinical information on other family 88 
members was not available. 89 
 
 90 
Quantitative PCR (qPCR)  91 
APC transcript levels in leukocyte RNA were first determined within a healthy control 92 
cohort.  RNA was prepared from venous blood samples from 40 normal controls, 93 
including 7 unaffected adult relatives of NVI patients and 33 healthy individuals 94 
without a personal or family history of polyposis or CRC recruited through a local 95 
study: Causes of Bowel Polyps: Recruitment of Healthy Controls (approved by Cardiff 96 
University School of Medicine Ethics Committee).  RNA was converted to cDNA, which 97 
underwent qPCR using Taqman technology (details of experimental protocols are in 98 
Supplementary 1 and 2, available at the European Journal of Human Genetics 99 
webpage).  cDNA from Individual 2.1 underwent qPCR using the same methods, along 100 
with a positive control with FAP due to a previously characterised APC promoter 101 
deletion that abrogated transcription, FAP1.  Results were analysed using 102 
ThermoFisher Cloud software, and APC expression levels in Individual 2.1 and the FAP 103 
positive control were compared to the healthy cohort to give an Rq value.  104 
 105 
Ultra-Deep Sequencing (UDS), Variant Calling and Validation in DNA 106 
UDS across the whole genomic locus of APC, hg19 chr5:g.112042936-112186350, was 107 
undertaken in genomic DNA extracted from whole blood from Individual 2.1.  108 
Reference sequence NM_001127511.2 was used, and the first delimited exon, which is 109 
untranslated, was assigned as Exon 1. 110 
Target sequence capture was undertaken using the Haloplex assay (Agilent).  111 
Sequencing was performed by the Wales Gene Park Genomics Facility 112 
 
(http://www.walesgenepark.cardiff.ac.uk/next-generation-sequencing/) using the 113 
HiSeq (Illumina). Rare variants, present in </= 1% of the population, according to 114 
dbSNP data or The 1000 Genomes Project data,  were analysed using CADD software 115 
(http://cadd.gs.washington.edu/home) and were assessed using the Integrative 116 
Genomics Viewer (IGV) (https://www.broadinstitute.org/igv/). Variants which had a 117 
CADD score >/= 15 were validated with Sanger sequencing (details in Supplementary 3, 118 
available at the European Journal of Human Genetics webpage).   119 
 120 
Results 121 
qPCR Studies 122 
The APC Rq value for FAP1 was 0.48 and for Individual 2.1 it was 0.56 (Mean delta Ct = 123 
8.238).  An assessment for APC allelic imbalance in Individual 2.1 was attempted but 124 
homozygosity for the chosen SNPs in her genomic DNA precluded informativity of the 125 
analysis. 126 
The qPCR results for all controls and NVI polyposis patients are in Supplementary 4, 127 
available at the European Journal of Human Genetics webpage.  A further 3 NVI 128 
polyposis patients also had apparently reduced APC expression, but the cause in these 129 
patients was not identified despite APC ultradeep sequencing, karyotype analysis 130 
where possible and APC promoter methylation studies.   131 
APC Capture and Ultra-Deep Sequencing (UDS) 132 
The mean depth of coverage across the APC locus for Individual 2.1 was 2458 reads, 133 
with 97.7% of the target region covered at a minimum of 1x read and 73.4% at a 134 
 
minimum of 1000x reads.  The APC promoter/Exon1 variant c.-190 G>A (hg19 135 
chr5:g.112043225 G>A) was identified in 2845/5546 (51%) reads and confirmed by 136 
Sanger sequencing.  It had a CADD score of 22.4. The pro a d s father a d o e ousi , 137 
both of whom also had a clinical diagnosis of FAP, were subsequently recruited for 138 
investigation (Figure 1 Individuals 1.1 and 2.2).  Both were found to carry the c.-190 139 
G>A variant. qPCR studies gave Rq values of 0.56 for the father and 0.63 for the cousin. 140 
The variant has been submitted to the LOVD database (patient ID 00213111). 141 
 142 
Discussion  143 
Li et al (2016) (ref 9) previously reported the APC c.-190 G>A variant in another family 144 
with FAP and profuse fundic gland polyposis, in which 5 individuals were affected over 145 
3 generations.  The authors performed electromobility shift assays showing that the 146 
variant led to reduced protein binding, and that the protein likely to be affected was 147 
the transcription factor YY1.  They demonstrated allelic imbalance of APC expression in 148 
carriers of the variant due to abrogation of transcription.   149 
This is consistent with the observation that truncating APC germline mutations usually 150 
do not result in nonsense mediated decay (NMD) (ref 10, reviewed in ref 11) so when 151 
reduced APC expression is identified, it may be more likely to result from reduced 152 
tra s riptio  aused  pro oter alteratio s rather tha  a issed  tru ati g aria t. 153 
I  Li s paper, other spe ifi  ger li e poi t utatio s i  the APC promoter 1B region 154 
resulted in a phenotype of gastric polyposis.  I di idual .  as fou d to ha e ultiple 155 
 
fu di  gla d pol ps i  the od  a d fu dus  he  she atte ded upper gastroi testi al 156 
endoscopic surveillance, but details of upper GI endoscopy could not be obtained for 157 
other family members. 158 
 The variant has been categorised as disease ausi g  (HGMD Accession CR165704) 159 
 and predictive genetic testing is now being offered to relatives of Individual 2.1.   160 
 161 
 162 
Our findings suggest that quantification of APC transcription may help to direct the 163 
search for an unusual underlying genetic mechanism in NVI patients with colorectal 164 
polyposis. 165 
Other studies have also demonstrated the importance of analysing transcripts in the 166 
search for unusual underlying mechanisms in NVI polyposis patients. As early as 1993, 167 
Powell et al (ref 12) used an allele-specific expression assay to show that 3/11 APC NVI 168 
patients with clinical FAP had significantly reduced expression of one APC allele. In 169 
1999 Laken et al (ref 13) used monoallelic mutation analysis (MAMA) to reveal that 7/9 170 
APC NVI patients had reduced/ no expression from one of their APC alleles. More 171 
recently Yan et al (ref 14) identified a patient with colorectal tumours and reduced 172 
levels of the APC protein.  This patient had the expected 50:50 APC allelic ratio in 173 
gDNA, but a 66:34 APC allelic ratio in cDNA from lymphoblastoid cells (ref 14).  Early 174 
findings regarding APC AI have been supported by Castellsagú et al (ref 15). Of 23 175 
APC/ MUTYH NVI polyposis families who were heterozygous for the SNP rs2229992, 2 176 
were shown to exhibit APC AI. The AI in one family was suggested to result from 177 
 
promoter variants (ref 15).  In 2012 transcript analysis in a sample of 125 NVI polyposis 178 
patients found that 8% had a reproducible aberrant transcript pattern, the majority of 179 
which reflected insertions between two exons originating from exonised sequences 180 
deep within the corresponding intron (ref 8).  181 
 182 
 183 
Considering APC qPCR studies, a rigorously determined Rq threshold would be 184 
required for diagnostic translation of transcription assays. With whole genome 185 
sequencing emerging as a realistic basis for genetic diagnosis it is likely that many 186 
more potentially regulatory non-coding variants will be identified in future. In this 187 
case, transcription studies and/or transcript analysis might form a second line test to 188 
provide evidence for or against their pathogenicity.  189 
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Figure legends 244 
Figure 1 Family Pedigree.  Proband is marked by an arrow (2.1) 245 
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Figure 247 
Figure 1 Family Pedigree. Proband is marked by an arrow (2.1) 248 
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